DENTSPLY SIRONA (XRAY) Stock Forecast & Price Target

Dentsply Sirona has demonstrated robust financial performance, highlighted by a double-digit percentage increase in orthodontics revenue, despite challenges with Byte in Q4/24. The firm reported substantial growth in Wellspect Healthcare, generating $88 million in revenue with a 6.9% increase and solid constant currency growth of 1.9%, underlining its resilience in diverse markets. Additionally, the Essential Dental Solutions segment reported $372 million in revenue, reflecting a 7.8% increase, with consistent growth noted in both reported and constant currency metrics, indicating a stable outlook for the company's comprehensive product portfolio.

Dentsply Sirona has revised its sales expectations downward, projecting a constant currency sales decline of -4% to -5%, compared to a previous forecast of -2% to -4%. Additionally, the company anticipates a decline in its GAAP gross margin and adjusted EBITDA margin, with expectations of a 160 basis point decrease in Q3/25 and a reduced adjusted EBITDA margin for FY/25, anticipated to exceed 18% but lower than prior estimates of over 19%. Furthermore, revenue from the connected technology solutions segment fell by 3.9%, indicating ongoing challenges, particularly in the orthodontics and implants segment, which is projected to decline by 15% due to headwinds related to its Byte clear aligner product.